{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-23-000097","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2023-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.907175+00:00","generated_at":"2026-06-14T07:16:34.708740+00:00","sec_items":["7.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Castle Biosciences reaffirms FY2023 revenue guidance of $170-180M and 2025 targets","bullets":["Reaffirms FY2023 total revenue guidance of $170-$180M.","Reaffirms 2025 total revenue target of $255-$330M.","Reaffirms target to achieve net operating cash flow positivity by 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-23-000097","json":"https://secwatch.observer/filing/0001447362-23-000097.json","markdown":"https://secwatch.observer/filing/0001447362-23-000097.md","text":"https://secwatch.observer/filing/0001447362-23-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000097/0001447362-23-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736223000097/cstl-20230605.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T07:16:34.708740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}